Our website is having a makeover! www.thecasecentre.org will be unavailable from 10h (BST) on Saturday 31 July until 17h on Sunday 1 August while our team makes the new site live.

Product details

Share this page:
Please find below the full details of the product you clicked a link to view.
Published by:
INSEAD (2016)
Revision date:
25 pages
Data source:
Field research


Sanofi Pasteur's newly approved dengue vaccine, Dengvaxia, was unusual in that it was launched in the Philippines and other at-risk countries. By choosing to 'flip the model' - launch in an emerging market setting as opposed to developed markets - it had to overcome various obstacles across the value chain, from registration to financing to supply. The company spent 20 years and invested USD1.7 billion to develop Dengvaxia, taking several high-risk decisions and making trade-offs along the way. The case highlights the stakeholder interdependencies and uncertainties that remained as the vaccine implementation programme crept closer. If successfully resolved, it could potentially offer a blueprint for others.


Public health; Infectious disease control; Vaccination program; Vaccine; Vaccine adoption; Infectious disease management; Global health; Emerging markets; Bottom of the pyramid; Health care innovation; Health sector stakeholders; Risk management; New product development
Other setting(s):

Access this item

View our pricing guide
or to see prices.

Reviews & usage